Keywords: Patent cliff, Leading drugs, Drugmakers, Humira, Avastin,
Pfizer will reign supreme after “patent cliff,” as Humira kicks Avastin off top spot, says EvaluatePharma
Article | 04 May 2010
US drug major Abbott Laboratories’ and Japanese firm Eisai’s rheumatoid arthritis treatment Humira (adalimumab) will replace global behemoth Pfizer’ ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
